Key Takeaways
- Abbott delivered Q1 earnings per share of $1.15, aligning with Wall Street projections of $1.14–$1.15
- Quarterly revenue reached $11.16 billion, surpassing the $11 billion consensus forecast
- The recently completed Exact Sciences acquisition strengthened cancer diagnostics performance
- Abbott’s flagship medical device division maintained strong momentum
- Second-quarter EPS outlook of $1.25–$1.31 trails the $1.32 analyst projection
Abbott Laboratories unveiled its first-quarter financial performance on April 16, delivering revenue figures that topped Wall Street projections, with meaningful contributions from its recently integrated cancer diagnostics operations.
The healthcare giant posted adjusted earnings per share of $1.15 during the three-month period. This figure aligned precisely with one analyst forecast of $1.15 and exceeded an alternative consensus estimate of $1.14 by a single cent, varying by analytical source.
Quarterly revenue totaled $11.16 billion, comfortably exceeding the $11 billion Wall Street had anticipated.
Shares settled at $101.56 prior to the earnings announcement. ABT has declined 16.59% during the preceding three-month span and has dropped 22.46% over the trailing twelve months.
The Exact Sciences transaction proved instrumental in shaping this quarter’s financial performance. Abbott reached an agreement in November to acquire the cancer diagnostics company for $105 per share through a transaction valued at approximately $23 billion. The acquisition finalized in March 2026.
This transaction represents among Abbott’s most significant acquisitions and signals a strategic expansion into oncology diagnostics. Performance from this newly integrated division contributed meaningfully to the first-quarter revenue outperformance.
Device Business Maintains Momentum
Abbott’s medical device division continues to represent its largest revenue generator. The segment delivered solid results in Q1, providing critical support for the company’s overall revenue beat.
The organization has consistently relied on its device operations as a primary growth engine throughout recent quarters. This pattern persisted during the opening three months of 2026.
Forward Outlook Trails Analyst Expectations
Looking ahead to Q2 2026, Abbott projected EPS in the range of $1.25 to $1.31. Wall Street analysts had established a consensus target of $1.32, positioning Abbott’s guidance midpoint marginally below market expectations.
For the complete fiscal year, Abbott anticipates EPS between $5.38 and $5.58. The analyst consensus stands at $5.47, which resides comfortably within Abbott’s projected range.
Abbott experienced zero upward EPS revisions and 18 downward revisions during the past 90 days. This represents a departure from the previous quarter’s “great performance” financial health classification — InvestingPro currently assigns Abbott a “good performance” financial health rating.
The revenue outperformance provides encouraging signals, despite guidance that failed to completely align with Wall Street expectations. Abbott’s Q1 top-line results emerged as the most compelling aspect of this quarterly report.
The full-year EPS consensus of $5.47 remains within Abbott’s projected band of $5.38 to $5.58, providing the company latitude to meet or exceed that benchmark as fiscal 2026 progresses.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
